COMMUNIQUÉS West-GlobeNewswire

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
06/05/2025
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated [...]
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
06/05/2025
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 – WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra [...]
Standard BioTools Reports First Quarter 2025 Financial Results
06/05/2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. [...]
Voyager Reports First Quarter 2025 Financial and Operating Results
06/05/2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on [...]
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06/05/2025
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today [...]
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
06/05/2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
WW International, Inc. Announces First Quarter 2025 Results
06/05/2025
Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical Subscribers Revenues of $186.6 million, down 9.7% vs. prior year period, including Clinical Subscription Revenues of $29.5 [...]
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
06/05/2025
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter [...]
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
06/05/2025
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year First quarter 2025 Total revenues of $462 million, up 33% year-over-year Medicare Advantage medical costs are in line with expectations [...]
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
06/05/2025
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin ( [...]
Amwell makes grant to new employee under inducement plan
06/05/2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to [...]
InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025
06/05/2025
DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
89bio to Participate in Upcoming Investor Conferences
06/05/2025
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
06/05/2025
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, [...]
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
06/05/2025
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds 1 of $16 million, revenue increased 5% year-over-year. First quarter 2025 Prenatal revenue grew 11% year-over-year [...]
LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance
06/05/2025
Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period Telehealth adjusted EBITDA increased to $5.3 [...]
Pennant Reports First Quarter 2025 Results
06/05/2025
Conference Call and Webcast scheduled for tomorrow, May 7, 2025 at 10:00 am MT EAGLE, Idaho, May 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated [...]
Supernus Announces First Quarter 2025 Financial Results
06/05/2025
First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI ® increased 16% to $30.7 million, compared to the same period in [...]
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
06/05/2025
SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the [...]

Pages